Novo Nordisk will lay off around 400 employees at its Bloomington site at the beginning of May, about a fifth of the drug manufacturing facility’s workforce.
Company spokesperson Stacy Beard confirmed the move in an email to the Indiana Daily Student on Monday. The move follows a tumultuous history for the Bloomington site, including several rounds of layoffs when Catalent owned it from 2017 to late 2024.
“We are deeply grateful to every impacted colleague and are committed to treating them with respect and dignity through this process, including severance, outplacement assistance and transition support,” Beard said.
Catalent, a third-party drug manufacturer, previously owned the site at 1300 S. Patterson Dr. Years of layoffs and alleged mismanagement under Catalent left many workers hopeful for Novo’s takeover bid, looking for a better company culture.
Novo Nordisk’s parent company completed its $16.5 billion acquisition of Catalent in December 2024. According to Novo’s website, the Bloomington site employs more than 1,800 people.
In September last year, the company announced it would cut 9,000 jobs, 4,000 of which would be outside of Denmark.
